Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadcal
- Development stage
- Unknown
- Lead developer
- Vats Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quadcal is an oral combination medication marketed by Vats Biotech, primarily used to manage calcium deficiency, support bone mineralization, and treat or prevent conditions such as osteoporosis. It is formulated as a fixed-dose combination containing calcium citrate (a highly bioavailable source of elemental calcium), calcitriol (the active form of vitamin D3 that enhances intestinal calcium absorption), magnesium hydroxide (which supports bone matrix preservation), and zinc sulfate (essential for bone tissue repair and enzymatic processes involved in bone remodeling).
- Brand names
- Quadcal
- Other names
- Quadcal Tablet
02
Targets
CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Quadcal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadcal.